C-Telopeptide (Endocrine Sciences)

TEST: 500089
Test number copied
CPT: 82523
Print Share

Synonyms

  • Carboxyterminal Cross-linking Telopeptide of Bone Collagen
  • Collagen Cross-linked C-Telopeptide
  • Crosslaps
  • Type 1 Collagen

Special Instructions

This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.

Expected Turnaround Time

3 - 5 days

Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.

Related Documents

Specimen Requirements

Specimen

Serum, frozen

Volume

0.5 mL

Minimum Volume

0.3 mL

Container

Gel-barrier tube

Collection

It is recommended to draw blood as fasting, morning samples. Samples should not be taken from patients receiving therapy with high biotin doses (i.e. >5 mg/day) until at least 8 hours following the last biotin administration.

Separate serum from cells within 45 minutes of collection. Transfer specimen to a plastic transport tube before freezing. To avoid delays in turnaround time when requesting multiple tests on frozen samples, please submit separate frozen specimens for each test requested.

Storage Instructions

Freeze.

Stability Requirements

Temperature

Period

Room temperature

1 day

Refrigerated

14 days

Frozen

2 years

Freeze/thaw cycles

Stable x6

Test Details

Use

For in vitro diagnostic use as an indicator of human bone resorption. This test may be used as an aid in monitoring bone resorption changes of antiresorptive therapies in postmenopausal women, individuals with osteopenia, and in predicting skeletal response (bone mineral density) in postmenopausal women undergoing antiresorptive therapies.

• Hormone replacement therapies (HRT) with hormones and hormone-like drugs

• Bisphosphonate therapies

Limitations

This test is not intended to predict the development of osteoporosis or future fracture risk. The use of this test has not been established in hyperparathyroidism or hyperthyroidism. When using the test to monitor therapy, results may be confounded in patients afflicted with clinical conditions known to affect bone resorption (eg, bone metastases, hyperparathyroidism, or hyperthyroidism). Results should be interpreted in conjunction with clinical findings and other diagnostic results and should not be used as a sole determination in initiating or changing therapy. Note: Serum values are not interchangeable with urine values.

Methodology

Electrochemiluminescence immunoassay (ECLIA)

Reference Interval

See table.

Gender

Range (pg/mL)

Male

38−724

Female

premenopausal

34−635

postmenopausal

34−1037

LOINC® Map

Order Code Order Code Name Order Loinc Result Code Result Code Name UofM Result LOINC
500089 C-Telopeptide, Serum 41171-0 502336 C-Telopeptide, Serum pg/mL 41171-0

For Providers

Please login to order a test

Order a Test

© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.

CPT Statement/Profile Statement

The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf